The OLIF Adoption Funnel Is a Spreadsheet. Here's What It Should Be.

Pick any mid-market spine company running surgeon education programs. Camber. ATEC. SI-BONE. Centinel. Treace. Paragon 28. Highridge. Doesn't matter which.

Ask the VP of Sales one question: of the surgeons who attended a lab in the last 12 months, how many have done their first case? How many have done five? How many have gone routine?

They will tell you they know the number. They won't be able to pull it up. Because the answer lives in a spreadsheet, a Salesforce dashboard, a rep's head, and three slide decks from quarterly meetings — and the four don't agree.

The most important workflow in mid-market spine sales is the surgeon adoption funnel. It's the actual product of the company.

The implants are the artifact. The intellectual property is real. But the asset — the thing that drives revenue quarter after quarter — is the network of surgeons who routinely use your product. And that asset is built one funnel stage at a time. Most companies in this market don't have a system for managing it.

The six stages, defined rigorously

Let me define what a real surgeon adoption funnel looks like, because most companies use these terms loosely and the looseness is part of the problem.

Stage 1 — Awareness. Surgeon knows your company exists. Has seen a rep at a conference, read an article, heard your name from a colleague. Has not engaged.

Stage 2 — Lab attended. Surgeon has physically attended a cadaveric training lab or a hands-on workshop. They've touched the instruments. They've watched a demonstration. They have opinions. This stage is where most companies declare premature victory. A surgeon attending a lab is not a surgeon adopting your product. It's the start of a conversation that takes nine to eighteen months to mature.

Stage 3 — Preceptored. Surgeon has completed a preceptored case — either at a KOL's institution observing, or at their own institution with a faculty surgeon walking them through it. The preceptor relationship is the most important conversion lever in the entire funnel. Companies with strong preceptor networks (Camber's OLIF program with Dr. John Williams in Fort Wayne is a textbook example) convert from this stage to the next at materially higher rates than companies running pure lab-based education.

Stage 4 — First independent case. Surgeon has performed their first solo case with your product. The rep is in the OR. The procedure goes well or doesn't. This is the moment of truth. A surgeon whose first case goes poorly almost never comes back. A surgeon whose first case goes well usually books a second within 30 days.

Stage 5 — Five cases done. Surgeon has done five or more cases. They're past the "is this product going to work for me" question and into the "is this going to fit my practice" question. They're comparing case times, outcomes, and reimbursement. They're forming a real opinion.

Stage 6 — Routine adopter. Surgeon is using your product as a default for the relevant indication. They're not just doing cases — they're modifying their referral and consultation patterns to use the procedure your product enables. They're talking to colleagues. They're a candidate to become a KOL or faculty member.

That's the funnel. Six stages, with measurable transitions between each one. Companies that track this rigorously have a meaningfully different operational picture than companies that don't.

What it actually looks like at most mid-market spine companies

Here's the reality on the ground at most $50-300M spine companies:

The marketing team tracks who registered for labs. The data lives in Eventbrite or HubSpot.

The clinical education team tracks who completed preceptor training. The data lives in Excel, maintained by one person who has been doing it for three years.

The sales reps track which surgeons did their first case. The data lives in their heads, in their territory plan documents, in private notes on their phones, and inconsistently in Salesforce.

The sales leadership team tracks routine adopters loosely. They know the top 20 surgeons by name. They have a vague sense of the next 50. Beyond that, the picture gets foggy.

Nobody has a unified view. The CEO asks for a quarterly report on funnel conversion and gets a slide that was assembled by hand by an ops person who pulled from four sources and made judgment calls about who counts as what.

This isn't because anyone is doing a bad job. It's because the systems weren't built to do this. Salesforce wasn't designed to track six-stage clinical education funnels. Spreadsheets don't talk to each other. The reps don't have time to manually update CRM fields after every case. The clinical education team is two people serving twelve regions.

The three hidden costs

The cost of this fragmentation shows up in three specific places, and the math is worse than most executives realize.

Stalled surgeon attrition

A surgeon who attends a lab and doesn't get follow-up within 30 days has roughly a 40% chance of going dark forever. A surgeon who completes preceptor training and doesn't book a first case within 60 days has roughly a 50% chance of never booking one. These aren't published statistics — they're the patterns every experienced spine sales VP recognizes when they look at their own data. The problem is that without a tracking system, nobody knows who is stalled at any given moment. Stalled surgeons sit in the funnel invisibly until they fall out, and nobody intervenes because nobody can see them.

For a company that runs ten labs a year with 15 surgeons per lab, that's 150 surgeons in the funnel. At industry-typical conversion rates, you'd expect maybe 60 to do a first case. With tight follow-up management, you can move that number to 75 or 80. That's 15-20 incremental surgeons per year, each of whom does an average of 8-12 cases at $4,000-8,000 in implant revenue. That's $480,000 to $1.9M in incremental revenue per year just from not letting people stall in your existing pipeline.

QBR friction

Every quarter, sales leadership runs a QBR. Half the conversation is reps explaining to leadership what leadership should already know — which surgeons are progressing, which are stalled, which need attention. It's a recurring tax on senior-rep and senior-management time that compounds. I've sat in QBRs where the VP of Sales spent 45 minutes asking reps about specific surgeons they should have had visibility into through a system. Multiply that by 12 reps, 4 QBRs a year, and you're looking at meaningful hours of senior commercial leadership time spent on what should be a dashboard.

Marketing ROI invisibility

Companies are spending real money on cadaveric labs. A multi-city OLIF lab series can cost $200,000-500,000 a year between facilities, cadavers, faculty fees, hospitality, and rep time. Leadership cannot answer with confidence: of the surgeons who attended last year's labs, what percentage are now routine adopters? They have a guess. They don't have a number. So the lab program runs on faith, expanding or contracting based on rep feedback rather than measured outcomes. In a PE-backed company, this is a real problem — the sponsor will eventually ask for the number, and the answer better not be "we believe it's working."

What the AI-enabled version looks like

The technology to fix this is not hard. The will to deploy it is the bottleneck.

A real funnel-tracking system has four components.

First, a unified data layer. Surgeon records flow from event registration, clinical education, Salesforce, and the rep's own notes into one structured database. The agent that does this isn't doing AI magic — it's doing the boring work of standardizing names, deduplicating records, and inferring stage based on the most recent activity. This is solved technology. Anyone telling you it requires a 12-month custom build is overselling.

Second, automatic stage classification. An agent reads activity logs and determines which stage each surgeon is currently in. New lab attendance → Stage 2. New preceptor completion → Stage 3. First case logged in Salesforce → Stage 4. Five cases within 18 months → Stage 5. Routine pattern (consistent monthly volume) → Stage 6. Stage transitions get logged with timestamps. Stalled surgeons (no activity in X days based on their current stage) get flagged.

Third, the next-best-action engine. For every surgeon flagged as stalled, the agent generates a specific suggested action for the rep: send a follow-up email referencing their lab attendance, schedule a check-in call, offer a preceptor case at a specific institution. The rep gets these recommendations in their morning Slack digest or a mobile app. The rep can accept, modify, or dismiss. The system learns which surgeons respond to which kinds of outreach.

Fourth, the leadership dashboard. The VP of Sales, CEO, and chief commercial officer get a unified view of the funnel: where surgeons are stuck, which reps are converting fastest, which regions are underperforming, which education programs are producing routine adopters and which are producing lab tourists. This is the dashboard that should run the QBR — not a hand-assembled slide deck.

A reference case

The Camber Spine OLIF education program is worth describing because it's an unusually mature version of what a strong adoption funnel looks like, even if it's still managed mostly by hand.

Camber runs cadaveric OLIF labs across multiple cities throughout the year. Surgeons who attend labs are invited to a clinical preceptor program led by Dr. John Williams at ORTHO Northeast in Fort Wayne, Indiana. The preceptor program creates a personal connection that the lab alone doesn't. Surgeons who go through preceptoring move into first cases at materially higher rates than surgeons who only attended labs. The faculty network includes Dr. Williams, Dr. Luis Duarte, Dr. James Blankenship, Dr. Eric Emanski, and others — names that show up consistently in Camber's surgeon engagement work.

The structure is right. The science is right. The conversion mechanics are right. What's missing is the operational system that makes the structure self-reinforcing — that flags every stalled surgeon, generates every next-step recommendation, and gives leadership real-time visibility into which programs are working and which aren't.

This isn't a Camber-specific observation. It applies to almost every mid-market spine company running serious surgeon education. The companies that move from "good program managed by hand" to "good program operating as a system" will pull away from the rest of the field in the next 24-36 months.

The bigger point

Companies that win the next decade of spine will not be the ones with the best implants. The product gap between mid-market spine companies has narrowed dramatically over the past ten years. SPIRA, SPIRA-A Integrated, Camber's lineup competes credibly with anything Globus or NuVasive can field for the relevant indications. ATEC's product line competes with anything in MIS. Treace owns bunion correction. The product is no longer the differentiator.

The differentiator is the operating system that converts surgeon interest into routine adoption. That system can be built now, in 2026, with available technology. The companies that build it first will have a structural advantage that's hard to overcome — because the asset they're building (a managed surgeon adoption funnel that performs measurably better year over year) compounds.

Companies that keep tracking this in spreadsheets are leaving a defensible competitive position on the table. They don't see it yet because the QBR slide always says the program is working. But the question worth asking next quarter isn't "is the program working?" The question is "if we had this funnel running as a real operational system, how many more routine adopters would we have by year-end?"

The number, for most mid-market spine companies, is large enough to matter.